Abstract
Upper gastrointestinal tract tumors historically have a poor prognosis. The decision
to treat esophageal or gastric cancers by surgery, radiotherapy, systemic therapy,
or a combination of these treatment modalities should always be discussed multidisciplinary.
The introduction of immunotherapy has drastically transformed the treatment landscape
of multiple solid malignancies. Emerging data from early and late phase clinical trials
suggests that the use of immunotherapies that target immune checkpoint proteins such
as PD-1/PD-L1 result in superior overall survival in advanced, metastatic, or recurrent
esophageal and gastric cancer, whether or not with specific molecular characteristics
such as PD-L1 expression level or microsatellite instability. This review offers an
overview of the most recent advances in the field of immunotherapy treatment in esophageal
and gastric cancer.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics.CA Cancer J Clin. 2015; 65: 5-29https://doi.org/10.3322/caac.21254
- Are squamous and adenocarcinomas of the esophagus the same disease?.Semin Radiat Oncol. 2007; 17: 38-44https://doi.org/10.1016/j.semradonc.2006.09.007
- Esophageal Carcinoma.New England Journal of Medicine. 2014; 371: 2499-2509https://doi.org/10.1056/NEJMra1314530
- Patterns and trends in esophageal cancer mortality and incidence in Europe (1980-2011) and predictions to 2015.Ann Oncol. 2014; 25: 283-290https://doi.org/10.1093/annonc/mdt486
- Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2016; 27: v38-v49https://doi.org/10.1093/annonc/mdw350
- Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection.Diseases of the Esophagus. 1996; 9: 173-182https://doi.org/10.1093/dote/9.3.173
- Classification of adenocarcinoma of the oesophagogastric junction.Br J Surg. 1998; 85: 1457-1459https://doi.org/10.1046/j.1365-2168.1998.00940.x
- The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging.CA Cancer J Clin. 2017; 67: 93-99https://doi.org/10.3322/caac.21388
- Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.Ann Oncol. 2022; 33: 992-1004https://doi.org/10.1016/j.annonc.2022.07.003
- Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.Cell Commun Signal. 2022; 20: 44https://doi.org/10.1186/s12964-022-00854-y
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors.Nat Rev Clin Oncol. 2021; 18: 345-362https://doi.org/10.1038/s41571-021-00473-5
- PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.Hum Vaccin Immunother. 2019; 15: 1111-1122https://doi.org/10.1080/21645515.2019.1571892
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.Mol Cancer. 2019; 18: 155https://doi.org/10.1186/s12943-019-1091-2
- PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions.Oncologist. 2019; 24: S31-S41https://doi.org/10.1634/theoncologist.2019-IO-S1-s05
- Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.N Engl J Med. 2018; 378: 2078-2092https://doi.org/10.1056/NEJMoa1801005
- Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.Lancet. 2019; 394: 1929-1939https://doi.org/10.1016/S0140-6736(19)32222-6
- First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.N Engl J Med. 2018; 379: 2220-2229https://doi.org/10.1056/NEJMoa1809064
- Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies.Klin Onkol. 2017; 31: 35-39https://doi.org/10.14735/amko201835
- Immunotherapy use in oesophagogastric cancers-a review of the literature.Br J Cancer. 2022; 127: 21-29https://doi.org/10.1038/s41416-022-01751-4
- Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives.Biomark Res. 2020; 8: 35https://doi.org/10.1186/s40364-020-00212-5
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy.Lancet Oncol. 2016; 17: e542-e551https://doi.org/10.1016/S1470-2045(16)30406-5
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.Lancet. 2018; 392: 123-133https://doi.org/10.1016/S0140-6736(18)31257-1
- Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.Sci Rep. 2021; 11: 15907https://doi.org/10.1038/s41598-021-95372-1
- Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study.J Clin Oncol. 2022; 40: 3065-3076https://doi.org/10.1200/JCO.21.01926
- Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.Gastric Cancer. 2020; 23: 95-104https://doi.org/10.1007/s10120-019-00999-9
- Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens.Pathology. 2021; 53: 586-594https://doi.org/10.1016/j.pathol.2020.10.015
- A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.Mod Pathol. 2019; 32: 1646-1656https://doi.org/10.1038/s41379-019-0307-8
- Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.Gastric Cancer. 2016; 19: 466-471https://doi.org/10.1007/s10120-015-0519-7
- PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells.Cancer Immunol Res. 2015; 3: 1308-1315https://doi.org/10.1158/2326-6066.CIR-15-0116
- Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.J Transl Med. 2016; 14: 173https://doi.org/10.1186/s12967-016-0925-6
- PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison.Clin Cancer Res. 2017; 23: 4938-4944https://doi.org/10.1158/1078-0432.CCR-16-1821
- A Prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer.JAMA Oncol. 2017; 3: 1051-1058https://doi.org/10.1001/jamaoncol.2017.0013
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Science. 2016; 351: 1463-1469https://doi.org/10.1126/science.aaf1490
- Molecular determinants of response to anti-programmed cell death (pd)-1 and anti-programmed death-ligand 1 (pd-l1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing.J Clin Oncol. 2018; 36: 633-641https://doi.org/10.1200/JCO.2017.75.3384
- Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.N Engl J Med. 2018; 378: 2093-2104https://doi.org/10.1056/NEJMoa1801946
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types.Nat Genet. 2019; 51: 202-206https://doi.org/10.1038/s41588-018-0312-8
- Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma.Front Oncol. 2018; 8: 269https://doi.org/10.3389/fonc.2018.00269
- Frameshift events predict anti-PD-1/L1 response in head and neck cancer.JCI Insight. 2018; 3: e98811https://doi.org/10.1172/jci.insight.98811
- Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.Mol Cancer Ther. 2017; 16: 2598-2608https://doi.org/10.1158/1535-7163.MCT-17-0386
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.Science. 2018; 362https://doi.org/10.1126/science.aar3593
- Tumor mutational burden and response rate to PD-1 inhibition.N Engl J Med. 2017; 377: 2500-2501https://doi.org/10.1056/NEJMc1713444
- From tumor immunology to immunotherapy in gastric and esophageal cancer.Int J Mol Sci. 2018; 20: 13https://doi.org/10.3390/ijms20010013
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science. 2017; 357: 409-413https://doi.org/10.1126/science.aan6733
- Precision medicine becomes reality-tumor type-agnostic therapy.Cancer Commun (Lond). 2018; 38: 6https://doi.org/10.1186/s40880-018-0274-3
- Microsatellite instability as a biomarker for PD-1 blockade.Clin Cancer Res. 2016; 22: 813-820https://doi.org/10.1158/1078-0432.CCR-15-1678
- Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.J Clin Oncol. 2020; 38: 1-10https://doi.org/10.1200/JCO.19.02105
- PD-1 blockade in tumors with mismatch-repair deficiency.N Engl J Med. 2015; 372: 2509-2520https://doi.org/10.1056/NEJMoa1500596
- Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—the University of Texas MD Anderson Cancer Center experience.Cancer. 2017; 123: 4106-4113https://doi.org/10.1002/cncr.30953
- Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.N Engl J Med. 2021; 384: 1191-1203https://doi.org/10.1056/NEJMoa2032125
- Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs.Signal Transduct Target Ther. 2021; 6: 314https://doi.org/10.1038/s41392-021-00722-0
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2016; 27: v50-v57https://doi.org/10.1093/annonc/mdw329
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.Lancet Oncol. 2013; 14: 490-499https://doi.org/10.1016/S1470-2045(13)70102-5
- Effect of Fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial.JAMA Oncol. 2017; 3: 620-627https://doi.org/10.1001/jamaoncol.2016.5580
- Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma.N Engl J Med. 2022; 386: 449-462https://doi.org/10.1056/NEJMoa2111380
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.Lancet. 2021; 398: 759-771https://doi.org/10.1016/S0140-6736(21)01234-4
- Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.JAMA Oncol. 2020; 6: 1571-1580https://doi.org/10.1001/jamaoncol.2020.3370
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.Gastric Cancer. 2015; 18: 476-484https://doi.org/10.1007/s10120-014-0402-y
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010; 376: 687-697https://doi.org/10.1016/S0140-6736(10)61121-X
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.Nature. 2021; 600: 727-730https://doi.org/10.1038/s41586-021-04161-3
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Lancet. 2021; 398: 27-40https://doi.org/10.1016/S0140-6736(21)00797-2
- Gastric cancer, Version 2.2022, NCCN clinical practice guidelines in Oncology.J Natl Compr Canc Netw. 2022; 20: 167-192https://doi.org/10.6004/jnccn.2022.0008
- Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.Ann Oncol. 2022; 33: 1005-1020https://doi.org/10.1016/j.annonc.2022.07.004
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol. 2019; 20: 1506-1517https://doi.org/10.1016/S1470-2045(19)30626-6
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020; 21: 1353-1365https://doi.org/10.1016/S1470-2045(20)30445-9
National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers Version 1. 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed March 2nd, 2023.
- PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs.Cancer Res Treat. 2020; 52: 661-670https://doi.org/10.4143/crt.2019.718
- Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy.Clin Cancer Res. 2020; 26: 6453-6463https://doi.org/10.1158/1078-0432.CCR-20-2085
- Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma.J Clin Oncol. 2022; 40: 392-402https://doi.org/10.1200/JCO.21.01862
- Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials.JAMA Oncol. 2022; 8: 1456-1465https://doi.org/10.1001/jamaoncol.2022.3707
- Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score.ESMO Open. 2022; 7100380https://doi.org/10.1016/j.esmoop.2021.100380
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med. 2017; 9: 34https://doi.org/10.1186/s13073-017-0424-2
- The challenges of tumor mutational burden as an immunotherapy biomarker.Cancer Cell. 2021; 39: 154-173https://doi.org/10.1016/j.ccell.2020.10.001
- MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.Future Oncol. 2022; 18: 2465-2473https://doi.org/10.2217/fon-2022-0093
- VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study.Front Oncol. 2019; 9: 1320https://doi.org/10.3389/fonc.2019.01320
- TremelImumab and durvalumab combination for the non-operative management (NOM) of microsatellite instability (MSI)-high resectable gastric or gastroesophageal junction cancer: the multicentre, single-arm, multi-cohort, phase II infinity study.Cancers (Basel). 2021; 13: 2839https://doi.org/10.3390/cancers13112839
- LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.J Clin Oncol. 2022; 40 (TPS367-TPS367)https://doi.org/10.1200/JCO.2022.40.4_suppl.TPS367
Article info
Publication history
Published online: March 14, 2023
Accepted:
March 8,
2023
Received in revised form:
March 3,
2023
Received:
October 28,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
